The Financial Costs of Smoking in New Jersey

Aug.18.2022
The Financial Costs of Smoking in New Jersey
This study measures the lifetime financial cost of smoking in New Jersey, highlighting potential economic benefits of quitting.

A study has examined the pricing, healthcare costs, income loss, and other smoking-related expenses in the state of New Jersey to calculate the financial cost of smoking one pack of cigarettes per day for a lifetime. The collected data shows that residents of New Jersey will spend over $2 million throughout their lives.


A recent cross-sectional study of 68 male smokers residing in temporary accommodation in Brisbane, Australia suggests that a tobacco cessation campaign focused on promoting economic savings may be more effective than campaigns solely focused on smoking cessation to address the economic burden of smoking. This finding highlights the potential success of broader anti-smoking initiatives aimed at promoting the health of specific populations.


This paper argues that the economic benefits of quitting smoking may be a stronger motivator for homeless individuals than the potential health benefits. It correctly notes that smoking among vulnerable populations, such as the homeless or those in temporary housing, increases the likelihood of poor health and financial disadvantage.


The research team conducted a survey that investigated participants' history of smoking and attempts to quit, as well as their opinions on smoking cessation tools. The researchers also asked about awareness levels regarding the reinforcement of the smoking cessation support program, which is a free program funded by the local government.


Statement


This article is compiled based on information from a third party and is intended for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of its content. The translation of this article is solely for the purpose of industry exchange and research.


Due to limitations in the translation process, the compiled article may not express the original text accurately. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong-Macau-Taiwan-related, or foreign matters in terms of statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

U.S. Military Smoking Debate Spotlights E-Cigarettes and Nicotine Pouches as a “Bridge”
U.S. Military Smoking Debate Spotlights E-Cigarettes and Nicotine Pouches as a “Bridge”
At a policy forum hosted by The Hill and sponsored by PMI US, U.S. defense health officials, lawmakers and industry representatives discussed tobacco use in the military and explored the potential role of smoke-free nicotine products — including e-cigarettes and nicotine pouches — as transitional tools to help service members reduce reliance on combustible cigarettes.
PMI
Mar.23
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
Indonesia’s vape retailers adopt 21+ signage and ID verification requirements, report says
Indonesia’s vape retailers adopt 21+ signage and ID verification requirements, report says
RetailNews Asia reported that the Association of Indonesian Vape Retailers (Arvindo) has directed member stores to stop selling e-cigarettes to people under 21 and to display 21+ signage and verify customer age using valid identification.
Feb.27
Pennsylvania Lawmaker Seeks to Keep Vape Shops Away From Schools
Pennsylvania Lawmaker Seeks to Keep Vape Shops Away From Schools
A Pennsylvania lawmaker is seeking legislation that would require newly licensed vape shops to be located at least 1,000 feet away from K-12 schools in the state. The proposal was put forward by State Representative Chris Pielli.
Mar.11 by 2FIRSTS.ai
Pakistan Senate health panel weighs possible vape ban
Pakistan Senate health panel weighs possible vape ban
Sources say Pakistan’s Senate Standing Committee on Health is deliberating whether to impose a ban on vaping products, after holding a meeting on the health implications of vaping and the rising use of e-cigarettes nationwide.
Mar.04 by 2FIRSTS.ai
FDA Highlights Product Characterization as a Foundational Requirement in ENDS PMTA Reviews
FDA Highlights Product Characterization as a Foundational Requirement in ENDS PMTA Reviews
During its ongoing PMTA roundtable, FDA emphasized that product characterization is a foundational element in the review of electronic nicotine delivery systems (ENDS). The agency underscored the need for complete product identifying information, validation and verification of test methods on the specific product type, and the appropriate use of tobacco product master files (TPMFs) to support complex or proprietary ingredients in PMTA submissions.
Feb.10